Cover Image
市場調查報告書

全球消化性潰瘍治療藥市場

Global Peptic Ulcer Drugs Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 310426
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Back to Top
全球消化性潰瘍治療藥市場 Global Peptic Ulcer Drugs Market 2014-2018
出版日期: 2014年08月13日 內容資訊: 英文 83 Pages
簡介

消化性潰瘍,是胃和小腸的粘膜內層出現的病變,有腹痛和噁心、嘔吐、胃脹等症狀。原因主要是受到胃幽門桿菌的感染,以及OTC的非類固醇抗發炎藥物使用過度。全球消化性潰瘍治療藥市場,預計2013∼2018年以年複合成長率2.9%擴大。

本報告提供全球消化性潰瘍治療藥市場相關調查、今後的成長預測、各地區趨勢、市場課題、機會及威脅,及主要供應商簡介彙整。

第1章 摘要整理

第2章 簡稱清單

第3章 本報告的範圍

第4章 產品簡介

  • Nexium
  • Losec
  • Vimovo
  • Pariet
  • Selbex
  • Albis
  • Lanpra/ Prevacid
  • Dexilant
  • Takelda

第5章 市場調查方法

第6章 簡介

第7章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 產品研發線

  • 開發平台候補的重要資訊

第9章 各類藥物市場區隔

  • 質子幫浦抑制劑
  • H2受體拮抗劑
  • 胃粘膜保護劑

第10章 各地區市場區隔

第11章 購買標準

第12章 市場成長的促進要素

第13章 促進要素與其影響

第14章 市場課題

第15章 促進要素的影響與課題

第16章 市場趨勢

第17章 趨勢與其影響

第18章 供應商環境

  • 競爭模式
    • 主要消息
    • 合併、收購
  • 市場佔有率分析
  • 其他值得注意的供應商與未來期待的供應商

第19章 供應商分析

  • AstraZeneca plc
  • Daewoong Pharmaceutical
  • Eisai株式會社
  • 武田藥品工業株式會社

圖表

目錄
Product Code: IRTNTR4006

About Peptic Ulcer and Drugs Used for the Treatment

A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and enzymes in these organs. The symptoms of peptic ulcers are pain in the abdomen, nausea, vomiting, and bloated stomach. The major symptoms include bleeding from the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. Peptic ulcers are caused mainly by a Helicobacter pylori infection followed by the overuse of OTC NSAIDs such as Naproxen, Aspirin and Ibuprofen. Peptic ulcers can be of two types based on the site of the ulcer: gastric ulcer and duodenal ulcer.

TechNavio's analysts forecast the Global Peptic Ulcer Drugs market to grow at a CAGR of 2.9 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Peptic Ulcer Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of peptic ulcers that are available in the market.

TechNavio's report, the Global Peptic Ulcer Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Peptic Ulcer Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • AstraZeneca plc
  • Eisai Co. Ltd.
  • Daewoong Pharmaceutical Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.

Other Prominent Vendors

  • Daiichi Sankyo
  • Dr. Reddy's Laboratories
  • Eumedica
  • Ferring Pharmaceuticals
  • Horizon Pharma
  • Johnson and Johnson
  • Merck Sharp and Dohme
  • Otsuka Holdings
  • Pfizer
  • PharmaKing
  • Pozen
  • Rottapharm Madaus
  • Taiho Pharmaceutical
  • Zeria Pharmaceutical
  • Zuventus Healthcare

Market Driver

  • Increased Incidence of H. pylori Infections.

For a full, detailed list, view our report.

Market Challenge

  • Adverse Effect of PPIs.

For a full, detailed list, view our report.

Market Trend

  • Use of Combination Drugs.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

  • 04.1.1. Nexium
  • 04.1.2. Losec
  • 04.1.3. Vimovo
  • 04.1.4. Pariet
  • 04.1.5. Selbex
  • 04.1.6. Albis
  • 04.1.7. Lanpra/ Prevacid
  • 04.1.8. Dexilant
  • 04.1.9. Takelda

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Pipeline Portfolio

  • 08.1. Key Information for the Pipeline Candidates
    • 08.1.1. PA32540
    • 08.1.2. TAK-438
    • 08.1.3. Lafutidine
    • 08.1.4. D961H
    • 08.1.5. PMK-S005
    • 08.1.6. YF476

09. Market Segmentation by Class of Drugs

  • 09.1. Proton Pump Inhibitors
  • 09.2. H2 Receptor Antagonists
  • 09.3. Gastric Mucosal Protective Drugs
  • 09.4. Antacids
  • 09.5. Antibiotics
  • 09.6. Prostaglandin Agonists

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2013
  • 18.3. Other Prominent Vendors & Expected Future Vendors

19. Key Vendor Analysis

  • 19.1. AstraZeneca plc
    • 19.1.1. Key Facts
    • 19.1.2. Business Description
    • 19.1.3. Business Segmentation
    • 19.1.4. Business Strategy
    • 19.1.5. Revenue by Business Segmentation
    • 19.1.6. Revenue Comparison 2011-2013
    • 19.1.7. Sales Revenue by Geographical Segmentation
    • 19.1.8. Key Developments
    • 19.1.9. SWOT Analysis
    • 19.1.10. Strengths
    • 19.1.11. Weaknesses
    • 19.1.12. Opportunities
    • 19.1.13. Threats
  • 19.2. Daewoong Pharmaceutical
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation by Revenue 2013
    • 19.2.4. Business Segmentation by Revenue 2012 and 2013
    • 19.2.5. Geographical Segmentation by Revenue 2013
    • 19.2.6. Business Strategy
    • 19.2.7. Recent Developments
    • 19.2.8. SWOT Analysis
    • 19.2.9. Strengths
    • 19.2.10. Weaknesses
    • 19.2.11. Opportunities
    • 19.2.12. Threats
  • 19.3. Eisai Co
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Comparison between Revenue, Operating Income, and Net Income
    • 19.3.4. Sales by Geography
    • 19.3.5. Business Strategy
    • 19.3.6. Key Information
    • 19.3.7. SWOT Analysis
    • 19.3.8. Strengths
    • 19.3.9. Weaknesses
    • 19.3.10. Opportunities
    • 19.3.11. Threats
  • 19.4. Takeda Pharmaceuticals
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation by Revenue 2013
    • 19.4.4. Business Segmentation by Revenue 2013
    • 19.4.5. Geographical Segmentation by Revenue 2013
    • 19.4.6. Business Strategy
    • 19.4.7. Recent Developments
    • 19.4.8. SWOT Analysis
    • 19.4.9. Strengths
    • 19.4.10. Weakness
    • 19.4.11. Opportunities
    • 19.4.12. Threats

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Peptic Ulcer Drugs market 2013-2018 (in US$ million)
  • Exhibit 3: Snapshot of Pipeline Drugs 2013
  • Exhibit 4: Global Peptic Ulcer Drugs Market Segmentation by Class of Drugs
  • Exhibit 5: Global Peptic Ulcer Drugs Market Segmentation by Class of Drugs 2013
  • Exhibit 6: Global Peptic Ulcer Drugs market by Geographical Segmentation
  • Exhibit 7: Global Peptic Ulcer Drugs Market Share Analysis 2013
  • Exhibit 8: Sales Comparison of AstraZeneca's Peptic Ulcer Drugs 2011-2013 (US$ million)
  • Exhibit 9: Sales of Nexium for the Period of 2008-2013 (US$ million)
  • Exhibit 10: Sales of Losec for the Period 2009-2013 (US$ million)
  • Exhibit 11: US Sales of Dexilant for the period 2009-2012 (US$ million)
  • Exhibit 12: Sales of Prevacid 2009-2012 (US$ million)
  • Exhibit 13: Sales of Pariet in Various Geographies in 2013 (US$ million)
  • Exhibit 14: AstraZeneca: Business Segmentation
  • Exhibit 15: AstraZeneca: Revenue by Business Segmentation 2013
  • Exhibit 16: AstraZeneca: Revenue by Business Segmentation 2011-2013 (US$ billion)
  • Exhibit 17: AstraZeneca: Sales Revenue by Geographical Segmentation 2013
  • Exhibit 18: Daewoong Pharmaceutical: Business Segmentation by Revenue 2013
  • Exhibit 19: Daewoong Pharmaceutical: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 20: Daewoong Pharmaceutical: Geographical Segmentation by Revenue 2013
  • Exhibit 21: Eisai: Comparison between Revenue, Operating Income, and Net Income 2011-2013 (US$ billion)
  • Exhibit 22: Eisai: Sales by Geography 2013 (US$ billion)
  • Exhibit 23: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
  • Exhibit 24: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
  • Exhibit 25: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013
Back to Top